565 related articles for article (PubMed ID: 36508072)
21. Clinicopathological characteristics of
Dugay F; Llamas-Gutierrez F; Gournay M; Medane S; Mazet F; Chiforeanu DC; Becker E; Lamy R; Léna H; Rioux-Leclercq N; Belaud-Rotureau MA; Cabillic F
Oncotarget; 2017 Aug; 8(32):53336-53351. PubMed ID: 28881815
[TBL] [Abstract][Full Text] [Related]
22. Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward.
Malapelle U; Muscarella LA; Pisapia P; Rossi A
Expert Opin Investig Drugs; 2020 Apr; 29(4):363-372. PubMed ID: 32073317
[No Abstract] [Full Text] [Related]
23. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.
Michelotti A; de Scordilli M; Bertoli E; De Carlo E; Del Conte A; Bearz A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743191
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
Facchinetti F; Proto C; Minari R; Garassino M; Tiseo M
Handb Exp Pharmacol; 2018; 249():63-89. PubMed ID: 28332047
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
26. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Tan AC; Tan DSW
J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
[TBL] [Abstract][Full Text] [Related]
27. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
28. Emerging oncogenic fusions other than
Suda K; Mitsudomi T
Transl Lung Cancer Res; 2020 Dec; 9(6):2618-2628. PubMed ID: 33489822
[TBL] [Abstract][Full Text] [Related]
29. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Ferrara MG; Di Noia V; D'Argento E; Vita E; Damiano P; Cannella A; Ribelli M; Pilotto S; Milella M; Tortora G; Bria E
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397295
[TBL] [Abstract][Full Text] [Related]
30. Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer.
Guo Y; Cao R; Zhang X; Huang L; Sun L; Zhao J; Ma J; Han C
Onco Targets Ther; 2019; 12():10343-10360. PubMed ID: 31819518
[TBL] [Abstract][Full Text] [Related]
31. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
Steeghs EMP; Groen HJM; Schuuring E; Aarts MJ; Damhuis RAM; Voorham QJM; ; Ligtenberg MJL; Grünberg K
Lung Cancer; 2022 May; 167():87-97. PubMed ID: 35461050
[TBL] [Abstract][Full Text] [Related]
32. [Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].
Suda K; Mitsudomi T
Kyobu Geka; 2022 Jan; 75(1):53-66. PubMed ID: 35249077
[TBL] [Abstract][Full Text] [Related]
33. Non-Small-Cell Lung Cancer: New Rare Targets-New Targeted Therapies-State of The Art and Future Directions.
Stencel K; Chmielewska I; Milanowski J; Ramlau R
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921237
[TBL] [Abstract][Full Text] [Related]
34. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
Roys A; Chang X; Liu Y; Xu X; Wu Y; Zuo D
Cancer Chemother Pharmacol; 2019 Oct; 84(4):679-688. PubMed ID: 31256210
[TBL] [Abstract][Full Text] [Related]
35.
Dong YU; Ren W; Qi J; Jin BO; Li Y; Tao H; Xu R; Li Y; Zhang Q; Han B
Oncol Lett; 2016 Apr; 11(4):2371-2378. PubMed ID: 27073482
[TBL] [Abstract][Full Text] [Related]
36. Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
Volckmar AL; Christopoulos P; Kirchner M; Allgäuer M; Neumann O; Budczies J; Rempel E; Horak P; Glade J; Goldschmid H; Seker-Cin H; Brandt R; Kriegsmann M; Leichsenring J; Winter H; Faehling M; Fischer JR; Heußel CP; Herth F; Brummer T; Fröhling S; Schirmacher P; Thomas M; Endris V; Penzel R; Kazdal D; Bochtler T; Stenzinger A
Lung Cancer; 2021 Apr; 154():131-141. PubMed ID: 33667718
[TBL] [Abstract][Full Text] [Related]
37. Beyond
Gkolfinopoulos S; Mountzios G
Ann Transl Med; 2018 Apr; 6(8):142. PubMed ID: 29862231
[TBL] [Abstract][Full Text] [Related]
38. New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).
Russo A; Lopes AR; McCusker MG; Garrigues SG; Ricciardi GR; Arensmeyer KE; Scilla KA; Mehra R; Rolfo C
Curr Oncol Rep; 2020 Apr; 22(5):48. PubMed ID: 32296961
[TBL] [Abstract][Full Text] [Related]
39. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
40. Targeting molecular alterations in non-small-cell lung cancer: what's next?
López-Castro R; García-Peña T; Mielgo-Rubio X; Riudavets M; Teixidó C; Vilariño N; Couñago F; Mezquita L
Per Med; 2022 Jul; 19(4):341-359. PubMed ID: 35748237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]